UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities
Issued Date
2024-01-01
Resource Type
ISSN
09546634
eISSN
14711753
Scopus ID
2-s2.0-85188447498
Pubmed ID
38508226
Journal Title
Journal of Dermatological Treatment
Volume
35
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Dermatological Treatment Vol.35 No.1 (2024)
Suggested Citation
Staubach P., Bilo B., Fluhr J.W., Krause K., Kulthanan K., Salman A., Katelaris C., Bernstein J.A., Maurer M., Mann C. UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities. Journal of Dermatological Treatment Vol.35 No.1 (2024). doi:10.1080/09546634.2024.2329784 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/97830
Title
UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: There is a lack of real-life safety data on treatment options for chronic urticaria in the presence of comedication and comorbidities. Methods: We present a single-center UCARE pilot study of 212 outpatients with chronic urticaria. Patients were divided into three groups according to different CU therapies according to international guidelines. Results: Of 212 patients, 108 (mean age 48.9 years, 71.3% female) had 59 comorbidities, including cardiovascular, autoimmune and malignant diseases. Patients were followed for a mean of 24.6 months (SD ± 21.3). Urticaria therapies were divided into three groups: A: 105 (97.2%) with omalizumab and 2nd generation antihistamines), B: 16 patients (14.8%): dual therapy with antihistamines and cyclosporine in 10 (9.3%), montelukast in five (4. 6%), dapsone in four (3.7%), hydroxychloroquine in one patient (0.9%), C: 12 (11.1%) patients received a third drug for 4.9 months (SD ± 3.2) and one quadruple therapy (2.1 months). 10 out of 12 (83.3%) patients received montelukast, two (16.7%) cyclosporine, two (16.7%) dapsone and one (8.3%) hydroxychloroquine as a third drug for chronic urticaria. Conclusions: Combining treatment modalities for chronic urticaria and comorbidities are available and feasible with a good safety profile.